Immuneering Corporation - Class A Common Stock (IMRX)

Let's have a look at the stocks with an unusual volume in today's session.

After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Curious to know what's happening on the US markets one hour before the close of the markets on Wednesday? Join us as we explore the top gainers and losers in today's session.

Immuneering reveals promising Phase 2a pancreatic cancer trial updates for IMM-1-104, showcasing efficacy, safety, and future expansion plans.

Up nearly 25% in today's session on a fast track designation for a key pancreatic cancer drug candidate, IMRX stock is coming into focus.

Wondering how the US markets performed in the middle of the day on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis.

The company plans to launch a pivotal trial in 2026 and expects additional clinical data and regulatory feedback by the end of 2025.

Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.

In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.

The trading landscape is alive with opportunity, shaped by a mix of macroeconomic events and sector-specific moves.

Discover today’s top stock opportunities with our 4-pillar strategy, combining catalysts, sentiment, fundamentals, and technicals to highlight 6 must-watch trades before the market opens.

Morgan Stanley downgrades Amicus Therapeutics, Immunocore, and Immuneering, citing pricing challenges, pipeline updates, and cautious growth outlooks.

A look at the 20 most searched tickers on Benzinga Pro, which includes many familiar names and some penny stocks that may be less familiar.

Immuneering reported promising initial response data from its Phase 2a trial for IMM-1-104 combined with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, showing a 40% response rate and 80% disease control rate.

IMRX stock results show that Immuneering missed analyst estimates for earnings per share the first quarter of 2024.